Ju Hyun Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ju Hyun Lee has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Jee Hyun Kim
Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea
3 shared publications - Sang-A Kim
Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Korea
3 shared publications - Soo-Mee Bang
Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Korea
3 shared publications - Eun Hee Jung
Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea
2 shared publications - Ho-Young Yhim
Department of Internal Medicine, Jeonbuk National University Medical School, Jeonju, South Korea
2 shared publications - Hun-Gyu Hwang
Soonchunhyang University Bucheon Hospital
2 shared publications
Latest Publications
- Open Access
- 1 January 2024
- Published by XMLink in Journal of Korean Medical Science
- Vol. 39 (36) , e252
Direct Oral Anticoagulants in Antiphospholipid Syndrome-Associated Venous Thromboembolism: Real World Evidence
Hwang HG, et al. J Korean Med Sci. 2024 Jul;39:e252. https://doi.org/10.3346/jkms.2024.39.e252
- 1 January 2024
- Published by XMLink in Journal of Korean Medical Science
- Vol. 39 (36) , e252
Open AccessDirect Oral Anticoagulants in Antiphospholipid Syndrome-Associated Venous Thromboembolism: Real World Evidence
Hwang HG, et al. J Korean Med Sci. 2024 Jul;39:e252. https://doi.org/10.3346/jkms.2024.39.e252
- Open Access
- 1 January 2024
- Published by XMLink in Journal of Korean Medical Science
- Vol. 39 (22) , e175
Skeletal-Related Events in Patients With Multiple Myeloma: A Comprehensive Retrospective Cohort Study
Lee JY, et al. J Korean Med Sci. 2024 May;39:e175. https://doi.org/10.3346/jkms.2024.39.e175
- 1 January 2024
- Published by XMLink in Journal of Korean Medical Science
- Vol. 39 (22) , e175
Open AccessSkeletal-Related Events in Patients With Multiple Myeloma: A Comprehensive Retrospective Cohort Study
Lee JY, et al. J Korean Med Sci. 2024 May;39:e175. https://doi.org/10.3346/jkms.2024.39.e175
- Open Access
- 1 January 2022
- Published by XMLink in Journal of Korean Medical Science
- Vol. 37 (17) , e130
Incidence of Venous Thromboembolism: The 3rdKorean Nationwide Study
Hwang HG, et al. J Korean Med Sci. 2022 Apr;37(17):e130. https://doi.org/10.3346/jkms.2022.37.e130
- 1 January 2022
- Published by XMLink in Journal of Korean Medical Science
- Vol. 37 (17) , e130
Open AccessIncidence of Venous Thromboembolism: The 3rdKorean Nationwide Study
Hwang HG, et al. J Korean Med Sci. 2022 Apr;37(17):e130. https://doi.org/10.3346/jkms.2022.37.e130
- Open Access
- 17 January 2021
- Published by Wiley in Thoracic Cancer
- Vol. 12 (5) , 619-630
Tumor LAG‐3 and NY‐ESO‐1 expression predict durable clinical benefits of immune checkpoint inhibitors in advanced non‐small cell lung cancer
Background: Immune checkpoint inhibitors (ICIs) are an established treatment for non‐small cell lung cancer (NSCLC) that have demonstrated durable clinical benefits (DCBs). Previous studies have suggested NY‐ESO‐1 and LAG‐3 to be surrogate markers of ICI responses in NSCLC; therefore, we explored the predictive value of their expression in NSCLC.Methods: We retrospectively reviewed the records of 38 patients with advanced NSCLC treated with anti‐PD‐1 monoclonal antibodies from 2013 to 2016 at Seoul National University Hospital and Seoul National University Bundang Hospital after failed platinum‐based chemotherapy. Tumor tissues from each patient were subjected to immunohistochemical analysis to determine NY‐ESO‐1, LAG‐3, and PD‐L1 expression, whose ability to predict progression‐free survival (PFS) and overall survival (OS) was then analyzed alongside their positive (PPV) and negative (NPV) predictive values.Results: NY‐ESO‐1 or LAG‐3 expression was detected in all tumor samples from patients with high PD‐L1 expression and was significantly associated with favorable outcomes, unlike PD‐L1 expression. Patients with both NY‐ESO‐1‐ and LAG‐3‐expressing tumors had a high DCB rate and those with triple‐positive PD‐L1, LAG‐3, and NY‐ESO expression had a superior median OS and PFS than those with triple‐negative expression. Furthermore, LAG‐3 and NY‐ESO‐1 co‐expression was an independent predictor of both PFS and OS, while LAG‐3 displayed a good NPV.Conclusions: Patients with NSCLC who co‐express NY‐ESO‐1 or LAG‐3 with PD‐L1 exhibit greater DCBs and improved long‐term survival following anti‐PD‐1 therapy. Moreover, NY‐ESO‐1 and LAG‐3 could be novel predictive biomarkers of survival and should be considered in the future use of ICIs.
- 17 January 2021
- Published by Wiley in Thoracic Cancer
- Vol. 12 (5) , 619-630
Open AccessTumor LAG‐3 and NY‐ESO‐1 expression predict durable clinical benefits of immune checkpoint inhibitors in advanced non‐small cell lung cancer
Background: Immune checkpoint inhibitors (ICIs) are an established treatment for non‐small cell lung cancer (NSCLC) that have demonstrated durable clinical benefits (DCBs). Previous studies have suggested NY‐ESO‐1 and LAG‐3 to be surrogate markers of ICI responses in NSCLC; therefore, we explored the predictive value of their expression in NSCLC.Methods: We retrospectively reviewed the records of 38 patients with advanced NSCLC treated with anti‐PD‐1 monoclonal antibodies from 2013 to 2016 at Seoul National University Hospital and Seoul National University Bundang Hospital after failed platinum‐based chemotherapy. Tumor tissues from each patient were subjected to immunohistochemical analysis to determine NY‐ESO‐1, LAG‐3, and PD‐L1 expression, whose ability to predict progression‐free survival (PFS) and overall survival (OS) was then analyzed alongside their positive (PPV) and negative (NPV) predictive values.Results: NY‐ESO‐1 or LAG‐3 expression was detected in all tumor samples from patients with high PD‐L1 expression and was significantly associated with favorable outcomes, unlike PD‐L1 expression. Patients with both NY‐ESO‐1‐ and LAG‐3‐expressing tumors had a high DCB rate and those with triple‐positive PD‐L1, LAG‐3, and NY‐ESO expression had a superior median OS and PFS than those with triple‐negative expression. Furthermore, LAG‐3 and NY‐ESO‐1 co‐expression was an independent predictor of both PFS and OS, while LAG‐3 displayed a good NPV.Conclusions: Patients with NSCLC who co‐express NY‐ESO‐1 or LAG‐3 with PD‐L1 exhibit greater DCBs and improved long‐term survival following anti‐PD‐1 therapy. Moreover, NY‐ESO‐1 and LAG‐3 could be novel predictive biomarkers of survival and should be considered in the future use of ICIs.
- Open Access
- 29 April 2019
- Published by Wiley in Journal of Cachexia, Sarcopenia and Muscle
- Vol. 10 (4) , 794-802
Impact of preoperative body compositions on survival following resection of biliary tract cancer
Background: Although surgical resection is the only potentially curative treatment for biliary tract cancer, the prognosis remains poor after a major operation such as pancreatoduodenectomy or hepatectomy. We aimed to investigate the impact of preoperative body compositions on long‐term survival of patients undergoing resection of biliary tract cancer.Methods: We analysed data of patients diagnosed with biliary tract cancer who underwent surgery from 2009 to 2015. Skeletal muscle area, skeletal muscle radiation attenuation, and visceral and subcutaneous adipose tissue areas were measured from the computed tomography images at L3 vertebral levels obtained before resection of cancer. Patients were divided into two groups based on the sex‐specific median values for each parameter, and long‐term survival was compared between the groups.Results: A total of 371 patients (women, 39.6%; mean age, 66.2 ± 9.6 years) were finally included in the analysis. Patients with low skeletal muscle index (SMI) had significantly shorter median survival than those with high SMI (29 vs. 39 months; P = 0.026). Patients with low skeletal muscle attenuation (SMA) also showed reduced survival compared with those with high SMA (median survival 25 vs. 60 months; P = 0.002). Combining these two factors, survival was highest in the high SMI/high SMA group (reference) and lowest in the low SMI/low SMA group (hazard ratio, 2.18; 95% confidence interval, 1.44–3.30). Visceral and subcutaneous adipose tissue areas were not associated with long‐term survival.Conclusions: Low SMI and low SMA on computed tomography scan have a negative impact on survival after resection of biliary tract cancer. They can be used in preoperative risk assessment to assist in treatment decision making.
- 29 April 2019
- Published by Wiley in Journal of Cachexia, Sarcopenia and Muscle
- Vol. 10 (4) , 794-802
Open AccessImpact of preoperative body compositions on survival following resection of biliary tract cancer
Background: Although surgical resection is the only potentially curative treatment for biliary tract cancer, the prognosis remains poor after a major operation such as pancreatoduodenectomy or hepatectomy. We aimed to investigate the impact of preoperative body compositions on long‐term survival of patients undergoing resection of biliary tract cancer.Methods: We analysed data of patients diagnosed with biliary tract cancer who underwent surgery from 2009 to 2015. Skeletal muscle area, skeletal muscle radiation attenuation, and visceral and subcutaneous adipose tissue areas were measured from the computed tomography images at L3 vertebral levels obtained before resection of cancer. Patients were divided into two groups based on the sex‐specific median values for each parameter, and long‐term survival was compared between the groups.Results: A total of 371 patients (women, 39.6%; mean age, 66.2 ± 9.6 years) were finally included in the analysis. Patients with low skeletal muscle index (SMI) had significantly shorter median survival than those with high SMI (29 vs. 39 months; P = 0.026). Patients with low skeletal muscle attenuation (SMA) also showed reduced survival compared with those with high SMA (median survival 25 vs. 60 months; P = 0.002). Combining these two factors, survival was highest in the high SMI/high SMA group (reference) and lowest in the low SMI/low SMA group (hazard ratio, 2.18; 95% confidence interval, 1.44–3.30). Visceral and subcutaneous adipose tissue areas were not associated with long‐term survival.Conclusions: Low SMI and low SMA on computed tomography scan have a negative impact on survival after resection of biliary tract cancer. They can be used in preoperative risk assessment to assist in treatment decision making.
- 20 May 2018
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 36 (15_suppl) , 10045
Prognostic benefit of taking statin and/or metformin in elderly patients with advanced non-small cell lung cancer: A nationwide population-based epidemiologic study.
10045Background: Comorbidities including dyslipidemia, diabetes and coronary heart disease are frequently found in elderly patients with advanced non-small cell lung cancer (NSCLC). Taking statin and/or metformin attenuates chronic inflammations, and could affect cancer outcomes. We aimed to evaluate prognostic impact of taking statin and/or metformin on survival in elderly patients with advanced NSCLC. Methods: Patients ≥ 70 years with advanced NSCLC incident from 2007 to 2012 were identified using reimbursement claims from Korea’s National Health Insurance Service Database, and exposures to statin and/or metformin were also documented. Cox proportional-hazards model and propensity score matched analysis were used to estimate the impact of drug exposures on overall survival (OS). Results: Excluding 976 treated by upfront anti-EGFR, 7298 receiving palliative chemotherapy were included: statin preparations were taken in 13.0%, metformin preparations in 13.8%, both in 3.5%, and neither in 76.6%, respectivel...
- 20 May 2018
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 36 (15_suppl) , 10045
Prognostic benefit of taking statin and/or metformin in elderly patients with advanced non-small cell lung cancer: A nationwide population-based epidemiologic study.
10045Background: Comorbidities including dyslipidemia, diabetes and coronary heart disease are frequently found in elderly patients with advanced non-small cell lung cancer (NSCLC). Taking statin and/or metformin attenuates chronic inflammations, and could affect cancer outcomes. We aimed to evaluate prognostic impact of taking statin and/or metformin on survival in elderly patients with advanced NSCLC. Methods: Patients ≥ 70 years with advanced NSCLC incident from 2007 to 2012 were identified using reimbursement claims from Korea’s National Health Insurance Service Database, and exposures to statin and/or metformin were also documented. Cox proportional-hazards model and propensity score matched analysis were used to estimate the impact of drug exposures on overall survival (OS). Results: Excluding 976 treated by upfront anti-EGFR, 7298 receiving palliative chemotherapy were included: statin preparations were taken in 13.0%, metformin preparations in 13.8%, both in 3.5%, and neither in 76.6%, respectivel...
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (15_suppl) , e20661
Prognostic benefit of statin with or without metformin in elderly patients with advanced non-small cell lung cancer: A nationwide population-based outcome study.
E20661 Background: Taking statin or metformin potentially decreases chronic inflammation, which may reduce cancer mortality as well as incidence. We aimed to clarify the prognostic impact of either use of metformin or statin in elderly patients with advanced non-small cell lung cancer (NSCLC). Methods: Patients ≥ 70 years with advanced NSCLC incident from 2007 to 2012 were identified using reimbursement claims from Korea’s National Health Insurance Service Database, and exposure to metformin and/or statin documented. Median overall survival (OS) was assessed by using Kaplan-Meier methods. Cox proportional-hazards regression model was used to examine the use of metformin and/or statin on mortality. Propensity score matching method adjusted for confounding. Results: Excluding 976 patients treated by upfront EGFR tyrosine kinase inhibitor, 7298 patients receiving palliative chemotherapy were included: 949 (13.0%) had a history of statin use, 1010 (13.8%) used metformin, 255 (3.5%) used both, and 5594 (76.6%) used neither. Median OS of statin + / metformin +, statin + / metformin –, statin - / metformin +, and statin - / metformin – users was 14.5, 12.9, 11.4 and 9.9 months respectively. By multivariate analyses, metformin use was not statistically significantly associated with improved survival in statin non-user (HR 0.99; 95% CI 0.91-1.08; p= 0.819) and statin user (HR 0.99; 95% CI 0.85-1.16; p= 0.898) group. However, use of statin, regardless of metformin, was associated with improved OS (HR 0.80; 95% CI 0.74-0.86; p< 0.001). In propensity-matched cohort, survival benefit was noted not by the use of metformin (HR 0.97; 95%CI 0.85-1.11; p= 0.661) but by the use of statin (HR 0.83; 95%CI 0.73-0.95; p= 0.007). Conclusions: Our findings did not suggest the survival benefit of metformin use in elderly patients with advanced NSCLC receiving palliative chemotherapy. Use of statin may provide a survival improvement in outcomes of elderly NSCLC.
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (15_suppl) , e20661
Prognostic benefit of statin with or without metformin in elderly patients with advanced non-small cell lung cancer: A nationwide population-based outcome study.
E20661 Background: Taking statin or metformin potentially decreases chronic inflammation, which may reduce cancer mortality as well as incidence. We aimed to clarify the prognostic impact of either use of metformin or statin in elderly patients with advanced non-small cell lung cancer (NSCLC). Methods: Patients ≥ 70 years with advanced NSCLC incident from 2007 to 2012 were identified using reimbursement claims from Korea’s National Health Insurance Service Database, and exposure to metformin and/or statin documented. Median overall survival (OS) was assessed by using Kaplan-Meier methods. Cox proportional-hazards regression model was used to examine the use of metformin and/or statin on mortality. Propensity score matching method adjusted for confounding. Results: Excluding 976 patients treated by upfront EGFR tyrosine kinase inhibitor, 7298 patients receiving palliative chemotherapy were included: 949 (13.0%) had a history of statin use, 1010 (13.8%) used metformin, 255 (3.5%) used both, and 5594 (76.6%) used neither. Median OS of statin + / metformin +, statin + / metformin –, statin - / metformin +, and statin - / metformin – users was 14.5, 12.9, 11.4 and 9.9 months respectively. By multivariate analyses, metformin use was not statistically significantly associated with improved survival in statin non-user (HR 0.99; 95% CI 0.91-1.08; p= 0.819) and statin user (HR 0.99; 95% CI 0.85-1.16; p= 0.898) group. However, use of statin, regardless of metformin, was associated with improved OS (HR 0.80; 95% CI 0.74-0.86; p< 0.001). In propensity-matched cohort, survival benefit was noted not by the use of metformin (HR 0.97; 95%CI 0.85-1.11; p= 0.661) but by the use of statin (HR 0.83; 95%CI 0.73-0.95; p= 0.007). Conclusions: Our findings did not suggest the survival benefit of metformin use in elderly patients with advanced NSCLC receiving palliative chemotherapy. Use of statin may provide a survival improvement in outcomes of elderly NSCLC.
- Open Access
- 1 January 2016
- Published by XMLink in Journal of Korean Medical Science
- Vol. 31 (6) , 963-971
Cataract and Cataract Surgery: Nationwide Prevalence and Clinical Determinants
Park SJ, et al. J Korean Med Sci. 2016 Jun;31(6):963-971. https://doi.org/10.3346/jkms.2016.31.6.963
- 1 January 2016
- Published by XMLink in Journal of Korean Medical Science
- Vol. 31 (6) , 963-971
Open AccessCataract and Cataract Surgery: Nationwide Prevalence and Clinical Determinants
Park SJ, et al. J Korean Med Sci. 2016 Jun;31(6):963-971. https://doi.org/10.3346/jkms.2016.31.6.963
- Open Access
- 1 January 2014
- Published by XMLink in Journal of Korean Medical Science
- Vol. 29 (7) , 957-964
The Clinical Association of the Blood Pressure Variability with the Target Organ Damage in Hypertensive Patients with Chronic Kidney Disease
Ryu J, et al. J Korean Med Sci. 2014 Jul;29(7):957-964. https://doi.org/10.3346/jkms.2014.29.7.957
- 1 January 2014
- Published by XMLink in Journal of Korean Medical Science
- Vol. 29 (7) , 957-964
Open AccessThe Clinical Association of the Blood Pressure Variability with the Target Organ Damage in Hypertensive Patients with Chronic Kidney Disease
Ryu J, et al. J Korean Med Sci. 2014 Jul;29(7):957-964. https://doi.org/10.3346/jkms.2014.29.7.957